Letter from the Editor

Dear Reader,

Thank you for your interest in Medicom’s summary of the ISTH 2020 congress. So far in 2020 we have transitioned to virtual congresses as we grapple with the COVID-19 pandemic. In spite of these challenges, this year’s meeting was rich with novel science ranging from haemophilia to venous thromboembolism.

Focused sessions on anticoagulation provide novel insights for patients with cancer and atrial fibrillation as well as use during pregnancy. Finally.

Focused sessions on COVID-19 continue to elucidate the underlying biology of this condition including associated inflammation and coagulopathy. Early data evaluating risk of thrombosis during and after hospitalization as well as the role of anticoagulation underscores the complexity of optimal treatment in this growing pandemic.

We hope you find these summaries balanced, insightful and interesting. Most of all, we hope you are safe and healthy, and we wish you the best during these challenging times.

Sincerely,

Marc Bonaca

 

Biography

Marc P. Bonaca, MD, MPH, is a Cardiologist and Vascular Medicine Specialist who serves as the Executive Director of CPC Clinical Research and CPC Community Health at the University of Colorado Anschutz Medical Campus. He is the Director of Vascular Research and an Associate Professor of Medicine at the University of Colorado School of Medicine and the inaugural holder of the William R. Hiatt Endowed Chair in Cardiovascular Research.

Dr Bonaca earned his medical degree from the University of Connecticut School of Medicine and his Masters in Public Health at Harvard University. He served as a Medical House Officer at Brigham and Women’s Hospital and Harvard Medical School. After completion of his training he joined the faculty of the Cardiovascular Division and Vascular Medicine section of Brigham and Women’s Hospital and Harvard Medical School and became an Investigator at the TIMI Study Group.

Dr Bonaca’s research focus is on ischemic risk in patients with atherosclerotic vascular disease, risk prediction, and risk modification through the use of pharmacologic and biologic therapies. His key areas of interest include patients with peripheral artery disease, polyvascular disease and diabetes with a focus on the breadth of risk including ischemic limb outcomes, microvascular complications and major adverse cardiovascular events.

Conflict of Interest Statement:

Grant support to BWH from AstraZeneca, MedImmune, Merck, PfizerGrant support to CPC from Amgen, AstraZeneca, Bayer, Janssen, NovoNordisk, Sanofi



Posted on 8 September, 20205 January, 2021